Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
Setsuko K. Chambers(University of Arizona), David S. Alberts(University of Arizona), Jeffrey D. Isaacs(University of Arizona), Mary C. Clouser(University of Arizona), Michael S. Gordon(Pinnacle Oncology Hematology), Raymond B. Nagle(University of Arizona), Heather Wright(University of Arizona), Amanda F. Baker(Roche (United States)), Alan N. Gordon(University of Arizona), Molly Brewer(UConn Health), Kenneth D. Hatch(Banner - University Medical Center Tucson), Mike F. Janicek(University of Arizona), Denise J. Roe(University of Arizona), Janice L. Cohen(University of Arizona), Haiyan Cui(Tongji University)
Cited by 55
Related Papers
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
|Journal of Clinical Oncology|2010|443
Non‐erosive reflux disease (NERD) — acid reflux and symptom patterns
|Alimentary Pharmacology & Therapeutics|2003|396